MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: spasticity"

  • 2019 International Congress

    Goal setting for botulinum toxin injections: Impact of the Upper Limb International Spasticity (ULIS) programme

    K. Fheodoroff, S. Ashford, J. Jacinto, A. Brashear, P. Maisonobe, A. Lysandropoulos, L. Turner-Stokes (Hermagor, Austria)

    Objective: The Upper Limb International Spasticity (ULIS) programme is a series of observational cohort studies across >30 countries. This analysis explores changes in goal setting…
  • 2019 International Congress

    AbobotulinumtoxinA: evidence for long duration of response

    K. Foster, A. Lysandropoulos, P. Picaut (Abingdon, United Kingdom)

    Objective: To assess clinical treatment intervals and duration of response for abobotulinumtoxinA in the management of pediatric and adult spasticity and assess preclinical data that…
  • 2019 International Congress

    An examination of real-world onabotulinumtoxinA utilization for the treatment of upper limb spasticity: The Adult Spasticity International Registry (ASPIRE) study

    G. Francisco, G. Bavikatte, W. Jost, D. Bandari, S. Tan Tang, A. Zuzek, A. Patel, J. Largent, A. Esquenazi (Taoyuan, Taiwan)

    Objective: To explore real-world patterns of onabotulinumtoxinA utilization in patients with upper limb spasticity over 2 years. Background: OnabotulinumtoxinA treatment for spasticity is variable, as…
  • 2018 International Congress

    5 Years’ Experience of Ixcellence Network®, an International Innovative Educational Program to improve Cervical Dystonia and Spastic paresis Management Practices

    C. Colosimo, T.M. Chung, L.J. Jacinto, K. Bahtia, T. Landreau, R. Bhidayasiri (Roma, Italy)

    Objective: To describe the impact of the Ixcellence® Network training program on physicians using botulinum neurotoxin-A (BoNT-A) in cervical dystonia (CD) and spastic paresis (SP).…
  • 2018 International Congress

    First Results from the Ixcellence Network® Survey: Botulinum Neurotoxin-A Usage and Training in Cervical Dystonia & Spastic Paresis

    R. Bhidayasiri, K. Bahtia, L.J. Jacinto, TM. Chung, T. Landreau, C. Colosimo (Bangkok, Thailand)

    Objective: To describe the current situation of training and practices among physicians using botulinum neurotoxin-A (BoNT-A) injections in the treatment of Cervical Dystonia (CD) and…
  • 2018 International Congress

    “Appropriate Doses Treatment” of IncobotulinumtoxinA in spasticity

    G. Ianieri, R. Marvulli (Bari, Italy)

    Objective: The aim of this study is to object the efficiency and safety of 100 to 1000 units botulinum toxin treatment with modulation of spasticity…
  • 2018 International Congress

    Evaluation of Effectiveness and Safety of Botulinum Toxin Type-A (BTX-A) for Chronic Focal Post-Stroke Upper Limb Spasticity in Indian Stroke Patients

    L. Basumatary (Guwahati, India)

    Objective: To evaluate the effectiveness and safety of Botulinum Toxin Type-A (BTX-A) for the treatment chronic focal post-stroke upper limb spasticity in Indian stroke patients.…
  • 2017 International Congress

    Efficacy of IncobotulinumtoxinA in Treatment of Lower Limb Spasticity in Adults

    D. Simpson, J. Wissel, D. Bensmail, A. Scheschonka, B. Flatau-Baqué, O. Simon (New York, NY, USA)

    Objective: To evaluate the effectiveness of incobotulinumtoxinA for treating key clinical patterns of lower limb (LL) spasticity (eg, pes equinovarus) using a post-hoc analysis. Background:…
  • 2017 International Congress

    Efficacy of IncobotulinumtoxinA for the Treatment Of Shoulder Spasticity

    D. Simpson, J. Wissel, D. Bensmail, A. Scheschonka, B. Flatau-Baqué, O. Simon (New York, NY, USA)

    Objective: To evaluate efficacy of botulinum toxin for shoulder spasticity using a post-hoc analysis. Background: Botulinum toxin has been shown to be effective for treating…
  • 2017 International Congress

    Effect of early AbobotulinumtoxinA (Dysport®) use after stroke on the time to reach reinjection criteria: asymptomatic versus symptomatic patients

    R. Rosales, K.J. Goh, W. Kumthornthip, M. Mazlan, L. Abdul Latif, M.M. DeLos Santos, C. Chotiyarnwong, P. Tanvijit, J. Balcaitiene, P. Maisonobe, K.-H. Kong (Manila, Philippines)

    Objective: To determine if early post-stroke (within 12 weeks) abobotulinumtoxinA (aboBoNT-A;Dysport®) injections delay appearance or progression of upper limb symptomatic spasticity. Background: Muscle tone changes…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley